Hypoglutamatergic state is associated with reduced cerebral glucose metabolism in anti-NMDA receptor encephalitis: a case report

Dominique Endres¹,²†, Evgeniy Perlov¹,²†, Oliver Stich³, Sebastian Rauer³, Simon Maier¹,², Zora Waldkircher¹, Thomas Lange⁴, Irina Mader⁵, Philipp Tobias Meyer⁶ and Ludger Tebartz van Elst¹,²*

Abstract

Background: Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis was first described in 2005 in association with ovarian teratoma. The diagnostic workup of this common autoimmune encephalitis includes cerebrospinal fluid analysis, electroencephalography, magnetic resonance imaging (MRI), and fluorodeoxyglucose positron emission tomography (FDG-PET). In addition to standard diagnostics, we performed metabolic investigations using proton magnet resonance spectroscopy (¹H-MRS).

Case presentation: We describe the case of a non-limbic anti-NMDAR encephalitis with a long course of disease (21 months). Laboratory diagnostics showed antibodies against NMDAR; an MRI revealed unspecific findings. ¹H-MRS indicated a hypoglutamatergic state in the left prefrontal cortex associated with a left hemispherical hypometabolism on FDG-PET. Despite the long course of disease, immunosuppressive therapy with methylprednisolone and azathioprine led to almost complete remission of clinical symptoms. Clinical improvement developed in parallel with remarkable normalization of cerebral glucose metabolism on FDG-PET.

Conclusion: This case of long-lasting extra-limbic anti-NMDAR encephalitis is of high clinical relevance. First, it illustrates that a very good outcome is possible even if adequate therapy is started only 21 months after the onset of severe symptoms. Second, it provides valuable insights into the pathophysiology of such anti-NMDAR encephalitis; these insights prove that anti-NMDAR encephalitis is linked not only to hyperglutamatergic signals but also to hypoglutamatergic states. These findings, contradictory at first glance, can be integrated within the model of excitatory/inhibitory imbalance and local area network inhibition.

Keywords: NMDA-receptor, Anti-NMDA-receptor-encephalitis, Glutamate, Magnetic resonance spectroscopy, Fluorodeoxyglucose positron emission tomography

Background

Immunological encephalopathies (IE) are increasingly recognized in psychiatry as rare but still important causes of clinical syndromes, which often present as atypical psychoses or affective disorders. IE may also present as a classical affective or psychotic syndrome without the hallmarks of organic causes. In this paper, we want to illustrate this new and complex clinical issue with respect to anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis by presenting a remarkable, severe, and chronic case of IE with positive outcome.

Anti-NMDA receptor encephalitis

The anti-NMDAR encephalitis was first described in 2005 in association with ovarian teratoma [1, 2], and was followed by an still increasing number of case reports and case series. In 2013, Titulaer and colleagues described 577 patients in the hitherto existing largest cohort study [3]. Some authors claim that anti-NMDAR encephalitis is the
second most frequent autoimmune encephalitis, after acute demyelinating encephalomyelitis [4].

Pathophysiologically, the initiation of anti-NMDAR-antibody production has yet to be understood in detail. In accordance with current theories, lymphocyte production is stimulated by a peripheral initiator, such as a tumor or infection. The disruption of the blood–brain barrier allows the passage of immune cells into the central nervous system (CNS) and leads to the clonal expansion of lymphocyte populations in the CNS, resulting in intrathecal antibody production [5]. Antibody binding to the NR1 subunit of the NMDA receptor leads to the internalization of the NMDA receptor via a cross-linking process with anti-Fab antibodies [6–8]. Internalization creates a reversible NMDAR hypofunction without the destruction of neurons or synapses [7, 9].

The clinical course of anti-NMDAR encephalitis is characterized by different phases of the disease: 1) prodromal period with headache, fever, or nausea; 2) psychiatric period with anxiety, paranoia, delusions, short-term memory loss, disintegration of language and sometimes mutism; 3) reduced consciousness; 4) hypoventilation; 5) seizures; 6) autonomic instability with, for example, hyperthermia, tachycardia, or urinary incontinence and dyskinesia; and 7) recovery in approximately 75 % or death [8, 10, 11]. In 60 % of patients, anti-NMDAR encephalitis is paraneoplastic, most often associated with ovarian teratoma [10]. The diagnostic workup includes cerebrospinal fluid (CSF) analysis, electroencephalography (EEG) and magnetic resonance imaging (MRI). Common differential diagnosis (especially infectious ones) should be clarified, and tumor screening should always be included in the diagnostic work up. The CSF examination shows initial abnormalities in 80 % of patients; protein concentration and white blood cell (WBC) counts are generally increased in a moderate way. CSF specific oligoclonal bands can be found in 60 % of patients. An intrathecal synthesis of anti-NMDA receptor antibodies is the most specific indicator [8]. EEG is abnormal in over 90 % of patients, and often shows diffuse slow activity [8, 10]. In 30 % of patients, a unique electrographic pattern called “extreme delta brush” was observed [12, 13]. In 50 % of the cases, the MRI has no pathological findings, while T2 or FLAIR hyperintensity is found in different regions in the remaining 50 % of cases [8]. Some studies showed abnormalities on fluorodeoxyglucose positron emission tomography (FDG-PET) or single-photon emission computed tomography [14–16].

Proton magnetic resonance spectroscopy (1H-MRS) might be another diagnostic tool to investigate anti-NMDAR encephalitis by measuring absolute concentrations of glutamate (Glu), glutamine (Gln), and the combined Glu and Gln signal, which is abbreviated as Glx.

Although randomized trials for the treatment of anti-NMDAR encephalitis are lacking, high-dose intravenous corticosteroids, plasma exchange, intravenous immunoglobulins, azathioprine and monoclonal antibodies (e.g., rituximab) are commonly used [17].

Neurometabolic imaging

The FDG-PET visualizes regional neuronal activity by measuring cerebral glucose (Glc) metabolism. However, only 1H-MRS allows non-invasive and non-radioactive measurement of Glu metabolism. 1H-MRS is a MR technique, that takes advantage of the fact that the resonance frequency of certain molecules reflects their structure and, thereby, their identity. 1H-MRS allows the absolute quantification of Glx, phosphorylcholine and glycerophosphorylcholine (t-Cho), N-acetylaspartate (NAA), creatine (Cre) and myo-inositol (ml). Glu is the major excitatory neurotransmitter in the human brain [18], while Gln is its storage and precursor form in astrocytes [19]. NAA is a marker of neuronal and axonal integrity. t-Cho is a marker for cell membrane turnover. Cre is often used as a concentration reference substance based on its constancy with respect to many pathologies. Finally, 1H-MRS allows the detection of ml, which is seen as a glial marker and part of the phosphatidyl-inositol second messenger system [20].

Case presentation

Specific characteristics

We present the case of a patient with an anti-NMDAR encephalitis, with a left prefrontal hypoglutamatergic status as measured with single-voxel 1H-MRS associated with a left hemispheric hypometabolism shown by FDG-PET. Despite the long duration of the disease, immunosuppressive therapy was successful.

Medical history

The patient is a 31-year-old woman who had worked successfully as a business controller for years. Twenty-one months prior to final diagnosis (day 0, onset), she experienced the first signs of personality change for approximately two weeks (mood changes and compulsive behaviors). Two months later, she experienced an epileptic seizure (for the first time), affective destabilization, cognitive deficits, and aggressiveness. Examination of the CSF showed an increased WBC count (23 /μl) and an elevated protein concentration (487 mg/l). No infectious cause was identified, and the MRI showed no pathological findings. Treatment was initiated with ceftriaxone and aciclovir for possible pathogenic agents, and clobazam and valproate for seizures. Despite treatment, the patient developed increasing mood changes, disorganized agitation behavior, partial amnesia, disinhibition, and ongoing aggressiveness. Additionally, she developed delusional symptoms and delirious states, which were
treated with antipsychotic medication and benzodiazepines, as several physicians involved in the case management preferred the diagnosis of schizophrenia. One month later (~day 90, onset), the patient developed a catatonic state with distinctive waxy flexibility and no reaction to strong pain stimuli. At that time, the diagnosis of catatonic schizophrenia was made. Two months later (~day 150, onset), the condition had improved, and the patient presented with a loss of energy, anxiety, and decelerated thinking, but without delusions, hallucinations or catatonic states. No further antipsychotic therapy was prescribed. Nearly one year later (~day 500, onset), the patient attended a neurological rehabilitation center. At that time, she still presented with loss of energy and pronounced difficulties in concentration. Furthermore, at that time, she was completely withdrawn socially. Because of psychotic and epileptic exacerbations, the diagnostic investigations were repeated (~day 540, onset). WBC count (20/μl) and protein concentration (550 mg/l) in the CSF were still elevated. A long-term EEG examination revealed a left temporal and right hemispherical brain dysfunction without epileptiform patterns. In the MRI, right temporo-occipital signal alterations were detected. A treatment with aciclovir, with the addition of piperacillin, was again unsuccessful. Psychotic symptoms increased and were treated again with antipsychotic drugs and high doses of tranquilizers. Meanwhile, anticonvulsive medication was changed to oxcarbazepine and lamotrigine. Neither medication was tolerated, due to leukopenia, thrombopenia, and exanthema; therefore, monotherapy was continued with valproate. The state of health deteriorated progressively with enuresis and an inability to eat, drink, and carry out personal hygiene. Twenty months after the first symptoms, the patient was admitted to the university clinic of psychiatry & psychotherapy Freiburg for further investigations.

Clinical presentation
On admission, the patient presented in a tired but fully conscious and oriented status. She showed difficulties in concentration, loss of memory, and disturbed speech production. On the first day, the patient already showed states of altered consciousness, mutism, and bizarre behavior. She answered questions with laughing, repeated single syllables (echolalia, palilalia), displayed fidgeting movements (right hand), showed ocular muscle contractions (left), was smacking her lips and displaying stereotypical movements. The patient was repeatedly frozen and showed symptoms of waxy flexibility.

Diagnostic results
In the CSF analysis, we found a blood–brain barrier disturbance (protein: 561 mg/l, albumin-quotient: 8.7), normal cell count (1/μl), and no intrathecal immunoglobulin synthesis. Serological screening for antibodies against neuronal cell surface antigens showed antibodies against the NMDA receptor. The analysis was performed in the reference laboratory at the Weatherall Institute of Molecular Medicine at John Radcliffe Hospital (Oxford, UK). EEG analysis showed an intermittent delta focus over the right central areas. In an additional independent component analysis of the EEG, we were able to describe three components: 1) right and left frontotemporal delta waves; 2) a deep right temporal generator; and 3) a central component including theta frequencies. MRI showed no specific findings; especially the hippocampal regions and structures of limbic system were without pathological findings. Moderate perisylvic/temporal accentuated atrophy was found (Fig. 1). On FDG-PET, global cortical hypometabolism of the left hemisphere was detected. A less pronounced hypometabolism was also detected on the right side, particularly of the temporal lobe. Cerebellar hypometabolism was found predominantly on the right side (most likely indicating crossed cerebellar diaschisis) (Fig. 2). 1H-MRS was performed in the prefrontal cortex (PFC) on both sides, using the standard single-voxel spectroscopy (voxel size 8 ml) Table 1. For spectroscopic analysis, the well-established and investigator-independent LCM (linear combination of model spectra) algorithm was used (www.s-provencher.com/pages/lcm.shtml) [21, 22]. In the PFC of the hypometabolic left hemisphere, we found distinct lower Glx

Fig. 1 Magnet resonance imaging (MRI) findings. MRI only shows a moderate perisylvic/temporal accentuated atrophy
concentrations compared with the opposite side. Glx/Cr ratios were also significantly decreased.

Therapeutic and clinical course
A diagnosis of anti-NMDAR encephalitis was established nearly 21 months after onset on the basis of typical clinical symptoms and the serological detection of antibodies against the NMDA receptor. We started an initial treatment with plasma exchange over 2 weeks (5 sessions) and prednisone (70 mg/d). However, this treatment did not lead to any improvement; therefore, after 10 days, we began a high-dose steroid pulse therapy (methylprednisolone 500 mg i.v./day for 5 days) and subsequently, a low-dose oral cortisone tapering until replacement with azathioprine as chronic maintenance therapy. Additionally, the antiepileptic medication was changed from valproate to levetiracetam. During and after the steroid pulse therapy, daily improvement was visible. Language production normalized and mood swings and disorganized behavior disappeared. The patient was discharged from the psychiatric department to the neuropsychiatric rehabilitation.

A second FDG-PET five months after the start of steroid treatment (~day 790, onset) indicated a nearly regular cerebral metabolism (Fig. 2). A slight frontal hypometabolism remained, probably due to frontal accentuated atrophy.

**Fig. 2** Fluorodeoxyglucose positron emission tomography (FDG-PET) findings. The initial FDG-PET scan (08/2010) depicted a global cortical hypometabolism of the left hemisphere, and, to a lesser extent, also of the right hemisphere; on the right side, hypometabolism was primarily located in the temporal lobe. Cerebellar hypometabolism was pronounced on the right side (most likely indicating crossed cerebellar diaschisis). The lower FDG-PET scan was acquired after successful immunosuppressive therapy (01/2011), indicating a nearly regular cerebral metabolism. A slight frontal hypometabolism remained most likely secondary due to frontal accentuated atrophy. Pronounced occipital metabolism is explainable by scan acquisition with open eyes. Both FDG-PET scans were performed at the Department of Nuclear Medicine of the University Hospital Freiburg after injection of 240 MBq 18FDG each (Gemini TF64 PET scanner, Philips Healthcare, The Netherlands).
In cognitive testing before discharge, slight deficits, particularly in working memory and mental flexibility, were still present. The repeated gynecological tumor screening for teratoma showed no pathological findings up to date.

Conclusion
Characteristics of our case report
We present the case of a 31-year-old woman with severe neuropsychiatric symptoms which were classified as schizophrenia or catatonic schizophrenia by several clinicians involved in case management but who in fact was suffering from an anti-NMDAR encephalitis. Neurometabolic investigations showed a left prefrontal hypoglutamatergic status in 1H-MRS associated with a left hemispheric hypometabolism on FDG-PET. To our knowledge, this is the first report of cortical hypoglutamatergic in vivo metabolism in anti-NMDAR encephalitis, illustrating that this mechanism might be of pathogenetic relevance in the genesis of psychiatric symptoms in such constellations. Despite the long duration of the neuroinflammatory process (21 months), immunosuppressive therapy was still successful. Clinical improvement paralleled the normalization of the metabolism on FDG-PET.

FDG-PET in autoimmune encephalitis
FDG-PET provides greater sensitivity for autoimmune encephalitis (78 %) compared with MRI (63 %) [23]. In our case report, we observed non-specific changes with MRI and remarkable abnormalities with the FDG-PET. In a retrospective analysis of FDG-PET findings with regard to autoimmune encephalitis, a significant association between autoantibody type and PET findings was described: in patients with autoantibodies against intracellular antigens, mainly mesiotemporal abnormalities were found, whereas normal findings or abnormalities outside the mesiotemporal region were more often detected in patients with autoantibodies against surface antigens, such as antibodies against the NMDA receptor [23]. Specifically, patients with anti-NMDAR encephalitis showed frontal and temporal Glc hypermetabolism associated with occipital hypometabolism (frontotemporal-to-occipital gradient). This pattern was positively associated with clinical disease severity. On longitudinal measurements of two patients, a normalization of cerebral Glc metabolism was identified [24]. We detected deviating FDG-PET results; in our case study, a global cortical hypometabolism was found in the left hemisphere, and, to a lesser degree, also in the right hemisphere. Moreover, cerebellar hypometabolism was identified, particularly on the right hemisphere, likely secondary to crossed cerebellar diaschisis. In our case, cortical hypometabolism might be the consequence of the long-term process which became apparent on FDG-PET 21 months after onset of the disease. By contrast, hypermetabolism in the frontotemporal regions might be an indicator of an acute disease phase [15], as Glc metabolism increases in active inflammation [25]. Consequently, in the study from Leyboldt and colleagues showing frontotemporal hypermetabolism, there was a distinctly shorter median time (median time was 10 weeks; range from 10 to 30 weeks) from the onset of the disease until FDG-PET imaging [24]. However, it is important to note that cortical hypometabolism did not indicate irreversible neuronal injury or post-inflammatory

| Metabolite concentration (in IU) (CRLB) | Metabolite ratio (/Cre) | Metabolite concentration (in IU) (CRLB) | Metabolite ratio (/Cre) |
|----------------------------------------|------------------------|----------------------------------------|------------------------|
| Glx                                    | 5.673 (12 %)           | 1.129                                  | 7.424 (8 %)            | 1.576                       |
| Cre                                    | 5.023 (3 %)            | 1.0                                    | 4.710 (3 %)            | 1.0                         |
| t-Cho                                  | 1.238 (3 %)            | 0.246                                  | 1.217 (3 %)            | 0.258                       |
| NAA + NAAG                             | 6.783 (3 %)            | 1.350                                  | 5.802 (3 %)            | 1.232                       |
| ml                                     | 3.815 (5 %)            | 0.760                                  | 3.295 (5 %)            | 0.699                       |

The MRS spectrum from the left prefrontal cortex shows lower concentrations of Glx compared with the opposite side. Glutamatergic hypometabolism correlated with a distinct hypometabolism in FDG-PET in this region; TR = 3000; TE = 30; NS = 64; voxel size = 8.0 mL. Abbreviations: CRLB = Cramér-Rao lower bounds; IU = Institutional Units; Glx = glutamate + glutamine; Cre = creatine; t-Cho = phosphorylcholine + glycerophosphorylcholine; NAA + NAAG = N-acetylaspartate + N-acetyl-aspartyl glutamate; ml = myo-inositol.
residuum in our case, because metabolism largely recovered upon treatment in parallel to clinical improvement.

**1H-MRS in autoimmune encephalitis**

To our knowledge, only two 1H-MRS measurements in anti-NMDAR encephalitis have been published to date [26, 27]. In the first case, NAA signals were initially decreased and normalized in the clinical course [26]. In the second case, reduced NAA concentrations were observed in the basal ganglia and thalamus at an early stage. Despite reduced NAA levels, MRI and EEG findings were unremarkable in this case. In late stage and after resolution of involuntary movements, NAA signals normalized [27]. In our case, we only detected a tendency towards higher NAA concentrations in the hypometabolic left hemisphere. However, we found evidence of decreased Glx signals and Glx/Cre ratios in the hypometabolic left hemisphere compared with the right side.

It is tempting to speculate that this underlies the observed, reversible hypometabolism on FDG-PET, which may be due to a persistent NMDAR hypofunctional state after the initial acute inflammatory and hypermetabolic phase observed by others. The reversibility of this process is likely the reason for the good prognosis of our patient, even though the pathogenetic process went untreated for nearly 21 months. The decrease of NMDA receptors directly correlates with the antibody titers [8]. Manto and colleagues performed in vivo experiments using Glu. They were able to identify increased Glu concentrations in the extracellular space. The increase was dose-dependent and much more pronounced with purified IgG [28].

**Excitatory/inhibitory dysbalance and local area network inhibition**

The findings of extracellular hyperglutamatergic states reported by Manto et al. [28] and our findings of hypoglutamatergic signal in 1H-MRS seem to be contradictory at first glance. However, they might well be integrated within the theoretical framework of excitatory/inhibitory dysbalance and local area network inhibition [29–31]. Similar results indicating a change from hyper- to hypoglutamatergic status are well known in epilepsy research. Excitatory seizure activity initially leads to an acute increase in Glx concentrations and a subsequent decrease in these concentrations over the course of the disease [29, 30, 32, 33]. A state of neuronal network instability as seen in epilepsy can be associated with local area hyperexcitability and hyperinhibition [31]. Therefore, we speculate that a model of a neuronal excitatory/inhibitory imbalance might explain the plethora of neuropsychiatric symptoms that can be observed in the course of NMDR encephalitis: Initial hyperglutamatergic states can be interpreted as an indicator of cortical over-excitation, whereas hypoglutamatergic states in the further course (after months) of the disease might be a sequel of over-inhibition of cortical brain areas, possibly triggered by the preceding over-excitation. We have recently put forward a model of local area network inhibition (LANI hypothesis) that is capable of explaining how states of excitatory/inhibitory dysbalances might translate pathogenetically into a plethora of neuropsychiatric symptoms typically seen in “organic psychiatric disorders” [31]. Such a model is also capable of explaining the symptoms of our patient. Initial and intercurrent hyperglutamatergic states might be linked to her hyperexcitability and symptoms such as seizures, whereas hypoglutamatergic states might be the cause for hyper-inhibition and symptoms like her mutistic and delirious states.

**Neuroinflammation and glutamatergic metabolism**

Furthermore, it is important to recognize that neuroinflammation is itself associated with altered glutamatergic metabolism. For example, the reduction of extracellular glutamate concentrations, through the intake of Glu into astrocytes, is disturbed during the inflammatory process [34]. Disturbed glutamate signals have also been shown to occur in neuroinflammatory diseases, such as HIV encephalopathy [35]. Thus, it seems reasonable to combine Glc (FDG-PET) and Glu (1H-MRS) measurements in cases in which anti-NMDAR encephalitis is suspected.

**Summary**

We presented the case of a 31-year-old woman with anti-NMDAR encephalitis. Neurometabolic investigations showed a left prefrontal hypoglutamatergic status on 1H-MRS associated with left hemispheric hypometabolism on FDG-PET. This case is remarkable because, to our knowledge, this is the first report on in vivo hypoglutamatergic status in anti-NMDAR encephalitis. The non-invasive measurement of the Glx signals via 1H-MRS might directly provide insights into the pathomechanism of anti-NMDAR encephalitis. In further studies, the combination of EEG, MRI, FDG-PET, and 1H-MRS should be performed during different stages of disease progression. Finally—and, clinically, even more important—our case report illustrates that even a retarded initiation of immunosuppressive therapy might be effective, and could lead to nearly full clinical remission.

**Consent**

The patient has given her consent for the details of the case report and for the figures to be published.
Contributing institutions
- Bayer Vital GmbH, Biogen Idec, Genzyme, Merck Serono, Novartis, Sanofi-Aventis and Teva.
- Roche Pharma AG, Germany; UCB Pharma GmbH, Germany.
- Freiburg Brain Imaging, University Medical Center Freiburg, Breisacher Str. 64, 79106 Freiburg, Germany.

Authors’ contributions
- EP and ZW treated the patient. DE and EP performed the CSF analysis. TL supported the revisions of the manuscript. IM critically reviewed the MR results, and PTM, the FDG-PET results. OS and SR critically reviewed the MR results, and PTM were crucially involved in the theoretical discussion and performing of the manuscript. All authors read and approved the final version of the manuscript.

Author details
- 1Section of Experimental Neuropsychiatry, Department for Psychiatry & Psychotherapy, University Medical Center Freiburg, Hauptstr. 5, 79104 Freiburg, Germany.
- 2Freiburg Brain Imaging, University Medical Center Freiburg, Breisacher Str. 64, 79106 Freiburg, Germany.
- 3Department of Neurology, University Medical Center Freiburg, Breisacher Str. 64, 79106 Freiburg, Germany.
- 4Department of Radiology, Medical Physics, University Medical Center Freiburg, Breisacher Str. 64, 79106 Freiburg, Germany.
- 5Department of Neuroradiology, University Medical Center Freiburg, Breisacher Str. 64, 79106 Freiburg, Germany.
- 6Department of Nuclear Medicine, University Medical Center Freiburg, Hugstetter Str. 64, 79106 Freiburg, Germany.

Received: 2 February 2015 Accepted: 6 July 2015
Published online: 01 August 2015

References
1. Vitaliani R, Mason W, Ances B, Zwerdling T, Jiang Z, Dalmau J. Paraneoplastic encephalitis, psychiatric symptoms, and hyperventilation in ovarian teratoma. Ann Neurol. 2005;58(4):594–604.
2. Dalmau J, Tüzün E, Wu H, Masjuan J, Ross J, Voloschuk A, et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol. 2007;61(1):23–36.
3. Titulaer MJ, McCracken L, Gabilondo I, Armanгуel T, Glazer C, Izuka T, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol. 2013;12(2):157–65.
4. Granero J, Ambrose HE, Davies NW, Clewley JP, Walsh AL, Morgan D, et al. Causes of encephalitis and differences in their clinical presentations in England: a multicentre, population-based prospective study. Lancet Infect Dis. 2010;10(12):835–44.
5. Ramanathan S, Mohammad SS, Brilot F, Dale RC. Autoimmune encephalitis: recent updates and emerging challenges. J Clin Neurosci. 2014;21(5):722–30.
6. Dalmau J, Gleichman AJ, Hughes EG, Ross J, Peng X, Lai M, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol. 2008;7(12):1091–8.
7. Hughes EG, Peng X, Gleichman AJ, Lai M, Zhou L, Tou R, et al. Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. J Neurosci. 2010;30(17):5866–75.
8. Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol. 2011;10(1):63–74.
9. Bien CG, Bauer J. Pathophysiology antikörperassoziierter ZNS-Erkrankungen. Nervenarzt. 2013;84(4):466–70.
10. Prüß H, Dalmau J, Arolt V, Wandinger K. Anti-NMDA-Rezeptor-Enzephalitis. Ein interdisziplinäres Krankheitsbild. Nervenarzt. 2010;81(4):396, 398, 400, passim.
11. Vincent A, Bien CG, Irani SR, Waters P. Autoantibodies associated with diseases of the CNS: new developments and future challenges. Lancet Neurol. 2011;10(8):759–72.
12. Schmitt SE, Parageon K, Fischette ES, Hirsch LI, Dalmau J, Friedman D. Extreme delta brush: a unique EEG pattern in adults with anti-NMDA receptor encephalitis. Neurology. 2012;79(11):1094–100.
13. Rosenfeld MR, Titulaer MJ, Dalmau J. Paraneoplastic syndromes and autoimmunoencephalitis: five new things. Neurology. 2012;79(11):235–40.
14. Maeder-Ingvart M, Prior JO, Irani SR, Rev Y, Vincent A, Rossetti AO. FDG-PET hyperintensity in basal ganglia correlating with clinical course in anti-NMDA-R antibodies encephalitis. J Neurol Neurosurg Psychiatry. 2011;82(2):235–6.
15. Pilits SC, Gill D, Webster R, Howman-Giles R, Dale RC. Cortical hypometabolism demonstrated by PET in relapsing NMDA receptor encephalitis. Pediatr Neurol. 2010;43(3):217–20.
16. Llorens V, Gabilondo I, Gómez-Esteban JC, Agundez M, Mendibe M, Bergara JC, et al. Abnormal multifocal cerebral blood flow on Tc-99 m HMPAO SPECT in a patient with anti-NMDA-receptor encephalitis. J Neurol. 2010;257(9):1568–9.
17. Peery HE, Day GS, Dunn S, Fritzler MJ, Prüß H, de Souza C, et al. Anti-NMDA receptor encephalitis. The disorder, the diagnosis and the immunobiology. Autimmnun Rev. 2012;11(12):683–72.
18. Novotny EJ, Fulbright RK, Pearl GM, Rothen LM. Magnetic resonance spectroscopy of neurotransmitters in human brain. Ann Neurol. 2003;54(6 Suppl):S25–31.
19. Govindaraju V, Youn K, Maudsley AA. Proton NMR chemical shifts and coupling constants for brain metabolites. NMR Biomed. 2000;13(3):129–33.
20. Ross B, Bown S. Magnetic resonance spectroscopy of the human brain. Anat Rec. 2001;265(2):54–84.
21. Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med. 1993;30(6):672–9.
22. Provencher SW. Automatic quantitation of localized in vivo 1H spectra with LCModel. NMR Biomed. 2001;14(4):260–4.
23. Baumgartner A, Rauer S, Mader I, Meyer PT. Cerebral FDG-PET and MRI findings in autoimmune limbic encephalitis: correlation with autoantibody types. J Neurol. 2010;260(1):74–53.
24. Leybold F, Buchert R, Kleiter I, Marienhagen J, Gelderblom M, Magnus T, et al. Fluorodeoxyglucose positron emission tomography in anti-N-methyl-D-aspartate receptor encephalitis: distinct pattern of disease. J Neurol Neurosurg Psychiatry. 2012;83(7):681–6.
25. Sekigawa M, Okumura A, Nijima S, Hayashi M, Tanaka K, Shimizu T. Autoimmune focal encephalitis shows marked hypermetabolism on positron emission tomography. J Pediatr. 2010;156(1):158–60.
26. Yamamoto S, Koide Y, Fujimura M, Nakazawa K, Takahashi Y, Hara H. Subacute encephalitis associated with anti-glutamate receptor antibodies: serial studies of MRI, 1H-MRS and SPECT. Rinsho Shinkeigaku. 2008;48(13):196–201.
27. Kataoka H, Dalmau J, Taoka T, Ueno S. Reduced N-acetylaspartate in the basal ganglia of a patient with anti-NMDA receptor encephalitis. Mov Disord. 2009;24(5):784–6.
28. Manto M, Dalmau J, Didekot A, Rogemond V, Honnorot J. In vivo effects of antibodies from patients with anti-NMDA receptor encephalitis: further evidence of synaptic glutamatergic dysfunction. Orphanet J Rare Dis. 2010;531.
29. Tebartz van Elst L, Maier S, Fangmeier T, Endres D, Mueller GT, Nickel K, et al. Disturbed circulat glutamate metabolism in adults with high-functioning autism spectrum disorder: evidence in support of the excitatory/inhibitory imbalance hypothesis. Mol Psychiatry. 2014;19(12):1314–25.
30. van Elst LT, Maier S, Fangmeier T, Endres D, Mueller GT, Nickel K, et al. Magnetic resonance spectroscopy comparing adults with high functioning autism and above average IQ. Mol Psychiatry. 2014;19(12):1251.
31. Tebartz van Elst L, Krishnamoorthy ES, Schulz-Bonhage A, Altmanmüller D, Richter H, Ebert D, et al. Local area network inhibition: a model of a potentially important pareaepileptic pathomechanism in neuropsychiatric disorders. Epilepsy Behav. 2011;22(2):231–9.
32. Doellen MT, Mennecke A, Staddlbauer A, Kecksmichl L, Kasper BS, Struffert T, et al. Multi-voxel magnetic resonance spectroscopy at 3 T in patients with idiopathic generalised epilepsy. Seizure. 2010;19(8):485–92.
33. Zahr NM, Crawford ELF, Hsu O, Vinco S, Mayer D, Rohlfing T, et al. In vivo glutamate decline associated with kainic acid-induced status epilepticus. Brain Res. 2009;1300:65–78.

34. Takaki J, Fujimori K, Miura M, Suzuki T, Sekino Y, Sato K. L-glutamate released from activated microglia downregulates astrocytic L-glutamate transporter expression in neuroinflammation: the ‘collusion’ hypothesis for increased extracellular L-glutamate concentration in neuroinflammation. J Neuroinflammation. 2012;9:275.

35. Chang L, Munsaka SM, Kraft-Terry S, Ernst T. Magnetic resonance spectroscopy to assess neuroinflammation and neuropathic pain. J Neuroimmune Pharmacol. 2013;8(3):576–93.